We are live on ! Find out more
OASM

Oasmia Pharmaceutical AB
OASM

Delisted

OASM was delisted on the 21st of August, 2019.

Back to rankings

5 hedge funds and large institutions have $113K invested in Oasmia Pharmaceutical AB in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

131% more capital invested

Capital invested by funds: $49K → $113K (+$64K)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

25% more funds holding

Funds holding: 4 → 5 (+1)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$39K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$32.5K
3
OMC
Old Mission Capital
Illinois
+$23.5K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$22K
2
UBS Group
UBS Group
Switzerland
-$2.51K

OASM Hedge Fund Activity: Q2 2018 in Review

5 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q2 2018, worth a combined $113K — up 131% from $49K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new OASM positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $39K. The largest seller was Citadel Advisors, exiting entirely with an estimated $22K sold.

  • 5 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q2 2018, up from 4 in Q1 2018.
  • Funds reported $113K of Oasmia Pharmaceutical AB stock for Q2 2018, up 131% quarter-over-quarter.
  • 2 funds opened new Oasmia Pharmaceutical AB positions in Q2 2018 and 1 closed out, a net change of +1 holder.
  • The largest Oasmia Pharmaceutical AB buyer in Q2 2018 was Jane Street, an estimated $39K added.
  • The largest Oasmia Pharmaceutical AB seller in Q2 2018 was Citadel Advisors, an estimated $22K sold.

Based on aggregated 13F filings for Q2 2018.